Pharmacokinetics of Tasimelteon Alone and in Combination With CYP1A2 Inhibitor, Fluvoxamine
Information source: Vanda Pharmaceuticals
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Healthy Volunteers
Intervention: Tasimelteon (Drug); Fluvoxamine (Drug)
Phase: Phase 1
Status: Completed
Sponsored by: Vanda Pharmaceuticals Official(s) and/or principal investigator(s): Vanda Pharmaceuticals, Study Director, Affiliation: Vanda Pharmaceuticals
Summary
The purpose of this research study is to evaluate whether administration of a CYP1A2
inhibitor affects the single-dose pharmacokinetics of tasimelteon and its metabolites. The
safety and tolerability of tasimelteon will also be assessed throughout the study.
Clinical Details
Official title: An Open-label, Single-sequence Study in Healthy Subjects to Evaluate the Single-dose Pharmacokinetics of Tasimelteon Alone and in Combination With a CYP1A2 Inhibitor, Fluvoxamine
Study design: Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science
Primary outcome: Tasimelteon pharmacokinetic parameters (AUC, Cmax, Tmax)
Secondary outcome: Safety and tolerability as measured by spontaneous reporting of AEs, and clinically significant changes in laboratory parameters, ECG parameters, and vital signsThe Columbia Suicide Severity Rating Scale will be used to assess suicidal behavior and ideation. Pharmacokinetic parameters (AUC, Cmax, Tmax) of tasimelteon metabolites M9, M11, M12, M13, and M14 Fluvoxamine pharmacokinetic parameters (AUC, Cmax, Tmax)
Eligibility
Minimum age: 18 Years.
Maximum age: 55 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
1. Men or women between 18 - 55 years, inclusive;
2. Non-smokers [abstinence from smoking for at least 6 months before the screening
visit] and test negative for cotinine at screening and baseline;
3. Subjects with Body Mass Index (BMI) of ≥18 and ≤35 kg/m2 (BMI = weight (kg)/ [height
(m)]2);
4. Males, non-fecund females (i. e., surgically sterilized, if procedure was done 6
months before screening or subject is postmenopausal, without menses for 6 months
before screening), or females of child-bearing potential using an acceptable method
of birth control for a period of 35 days before the first dosing and females must
have a negative pregnancy test at the screening and baseline visits;
5. Note 1: Acceptable methods of birth control include any one of the following:
abstinence, vasectomized sexual partner, hormonal methods (i. e. pill, hormonal IUD,
Depo-Provera, implants, patch, intravaginal device [NuvaRing]), intrauterine device
(IUD [copper banded coils]), diaphragm, cervical cap, or condom with spermicidal
jelly or foam.
6. Vital signs (after 3 minutes resting in a semi-supine position) which are within the
ranges shown below:
- Body temperature between 35. 0-37. 5 °C;
- Systolic blood pressure between 90-150 mmHg;
- Diastolic blood pressure between 50-95 mmHg;
- Pulse rate between 50-100 bpm.
7. Ability and acceptance to provide written informed consent;
8. Willing and able to comply with study requirements and restrictions;
9. Subjects must be in good health as determined by past medical history, physical
examination, electrocardiogram, clinical laboratory tests.
Exclusion Criteria:
1. History of recent (within six months) drug or alcohol abuse as defined in DSM IV,
Diagnostic Criteria for Drug and Alcohol Abuse or evidence of such abuse as indicated
by the laboratory assays conducted during the Screening Visit or at Baseline;
2. Any major surgery within three months of Baseline or any minor surgery within one
month;
3. History or current evidence of cardiovascular, hepatic, hematopoietic, renal,
gastrointestinal or metabolic dysfunction judged by the Investigator to be clinically
significant;
4. Subjects who are currently considered a suicide risk, any subject who has ever made a
suicide attempt, or those who are currently demonstrating active (within the last
year) suicidal ideation as deemed by the Columbia Suicide Severity Rating Scale
(C-SSRS);
5. Any condition requiring the regular use of medication except those listed on Section
8. 2;
6. Exposure to any investigational drug, including placebo, within 30 days or 5
half-lives (whichever is longer) of baseline;
7. Anyone who has taken a melatonin preparation chronically within the past two months
prior to Day 1;
8. Donation or loss of 400 mL or more of blood within two months prior to the Baseline
Visit;
9. Significant illness within the two weeks prior to Baseline;
10. A known intolerance or hypersensitivity to fluvoxamine, tasimelteon or drugs similar
to tasimelteon (including melatonin) or fluvoxamine;
11. Pregnant or lactating females;
12. History of liver disease and/or positive for one or more of the following serological
results:
- A positive hepatitis C antibody test (anti-HCV)
- A positive hepatitis B surface antigen (HBsAg)
- A positive HIV test result
13. Exposure (within 2 weeks of the Baseline Visit) of any over-the-counter medications
including dietary supplements and/or herbal remedies, except those listed on Section
8. 2;
14. Treatment with any drug known to cause major organ system toxicity (e. g.,
chloramphenicol or tamoxifen) during the 60 days preceding the Screening visit;
15. Participation in a previous BMS-214778/VEC-162 trial;
16. Use of any food or beverage containing grapefruit or grapefruit juice, apple or
orange juice, vegetables from the mustard green family (e. g. kale, broccoli,
watercress, collard greens, kohlrabi, Brussels sprouts, mustard greens) and
charbroiled meats for at least 2 weeks before the Baseline Visit until the end of the
study;
17. Inability to be venipunctured and/or tolerate venous access;
18. Subjects who are unable to read or speak English;
19. Any other sound medical reason as determined by the clinical Investigator.
Locations and Contacts
Bio-Kinetic Clinical Applications, Springfield, Missouri 65802, United States
Additional Information
Starting date: February 2012
Last updated: February 14, 2014
|